LDS/Medical Tests/Partner and Localizer of BRCA2 (PALB2) Gene Mutation Analysis

Partner and Localizer of BRCA2 (PALB2) Gene Mutation Analysis

The PALB2 gene, located in the short (p) arm of chromosome 16 at position 12.2 encodes Partner and localizer of BRCA2, also known as PALB2 or FANCN. The PALB2 protein binds to and colocalizes with the breast cancer 2 early onset protein (BRCA2) in nuclear foci and likely permits the stable intranuclear localization and accumulation of BRCA2 to form BRCA complex. The integrity of the BRCA complex is essential for the maintenance of genomic stability via recombinational. PALB2 act as a tumor suppressor protein by mediating DNA repair and thereby suppressing genome instability. Germline heterozygous mutations in PALB2 are associated with increased risk of breast and pancreatic cancer. Bi-allelic mutations in PALB2 cause a severe form of Fanconi anemia, subtype FA-N, with early onset of acute myeloid leukemia, medulloblastoma, neuroblastoma and often Wilms’ tumor, leading to early death in the first decade of life.

Fanconi anemia is a chromosomal instability syndrome inherited in both autosomal and X-linked patterns. Biallelic mutations in PALB2 lead to Fanconi anemia subtype N5. Patients with PALB2- related FA have a typical FA phenotype with growth retardation and variable congenital malformations. Furthermore, the PALB2-related FA phenotype is associated with an unusually severe predisposition to childhood solid tumors.

PALB2 mutations are found in 1% to 4% of BRCA1/BRCA2-negative familial breast cancer cases. Rare germline monoallelic mutations in PALB2 have been reported to confer a 5-9-fold increase risk for breast cancer. A number of monoallelic PALB2 truncating mutations and a novel PALB2 gene deletion were identified in women with a strong family history of breast cancer and negative mutations in BRCA1 and BRCA2. Further, the PALB2 gene has been recently identified as the second most important susceptibility gene for familial pancreatic cancer (FPC) after BRCA2.

  • As an aid in diagnosis of Fanconi anemia
  • As an aid in diagnosis of breast cancer
  • As an aid in diagnosis of ovarian cancer
  • As an aid in the diagnosis of Familial pancreatic cancer
Mutation or pathogenic variant in PALB2 gene supports diagnosis of Fanconi anemia and breast cancer. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative for mutations analyzed (No pathogenic variant or mutation detected)

Full gene sequencing of PALB2 gene by next-generation sequencing or bidirectional sequencing. Targeted testing for known familial mutation by Sanger sequencing. PALB2 gene-targeted deletion/duplication analysis by quantitative multiplex PCR, long-range PCR, multiplex ligation dependent probe amplification (MLPA).

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: unacceptable
Breast biopsy, array comparative genomic hybridization (aCGH), Breast cancer mutation panel by NGs, CA19-9 blood test, CA-125 blood test.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Atlas Genet Cytogenet Oncol Haematol. 2018; 22: 484–490. [PMID: 31413733]
  • J Breast Health. 2014; 10: 189. [PMID: 28331669]
  • N Engl J Med. 2014;371: 497-506. [PMID: 25099575]
  • Annu Rev Genet. 2009;43:223-49. [PMID: 19686080]
  • Breast Cancer Res. 2008;10:208. [PMID: 18557994]
  • GeneReviews® [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1401/
  • Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/PALB2#
  • The Breast (fifth edition) comprehensive management of benign and malignant diseases, In: chapter 17- breast cancer genetics: syndromes, genes, pathology, counseling, testing and treatment, 2018, 237-249. https://doi.org/10.1016/B978-0-323-35955-9.00017-9